Markedsføringstillatelser av legemidler til mennesker: erlotinib
Utkast til kommisjonsbeslutning godkjent av komite (representanter for medlemslandene) og publisert i EUs komitologiregister 21.9.2022
BAKGRUNN (fra kommisjonsbeslutningen, engelsk utgave)
(1) Medicinal products for human use authorised by the Member States must meet the requirements of Directive 2001/83/EC.
(2) Periodic safety update reports concerning medicinal products containing the same active substance were submitted. The reports were assessed by the Pharmacovigilance Risk Assessment Committee as to whether the marketing authorisations concerned should be maintained, varied, suspended or withdrawn.
(3) The scientific assessment performed by the Committee for Medicinal Products for Human Use, the conclusions of which are set out in Annex I to this Decision, shows that a decision should be taken amending the marketing authorisations for the medicinal products concerned.
(4) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Medicinal Products for Human Use,